Status:
TERMINATED
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
Lead Sponsor:
HaEmek Medical Center, Israel
Collaborating Sponsors:
T MAY BIOPHARMA LTD.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
19 COVID (Coronavirus disease 2019 ) is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19). Following IN-VITRO eviden...
Detailed Description
19 COVID is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19). This virus family causes upper respiratory tract dise...
Eligibility Criteria
Inclusion
- Age over 18
- A person diagnosed with COVID-19 in the past 48 hours
- Asymptomatic
Exclusion
- chronic lung disease with chronic hypoxia
- Sleep apnea requiring BIPAP / continuous positive airway pressure
- Retinal disease
- Porphyria
- Myastenia gravis
- immunodeficiency disorders
- Hearing Disorders
- Scheduled for general anesthesia
- treatment with antibiotics or antiretroviral for any reason
- Pulse \<50
- Known Ventricular arrhythmias
- Heart Failure: Systolic or Diastolic
- kown QT prolongation
- Taking medicines that increase the risk of QT prolongation in combination with CHLOROQUINE.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04333628
Start Date
June 1 2020
End Date
September 1 2020
Last Update
October 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haemek Medical Center
Afula, Israel